Abstracts tagged "Patient reported outcomes"

Abstract Number: 2342 • ACR Convergence 2025
Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
Andrew Ostor¹, Jessica A. Walsh², Christopher Saffore³, Xiaolan Ye⁴, Manish Patel⁵, Ana Biljan⁶, Jamie Vora⁷, Isabel Truman⁸, Molly Edwards⁸, Gary Milligan⁸ and William Tillett⁹, ¹Australian National University, Canberra, Australia, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Buffalo Grove, IL, ⁷AbbVie Inc., Palatine, IL, ⁸Adelphi Real World, Bollington, United Kingdom, ⁹Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: This study evaluated real-world effectiveness and patient- and physician-satisfaction with risankizumab (RZB) for biologic-naïve PsA patients with limited joint involvement or oligoarthritis.Methods: Data were…
Abstract Number: 1648 • ACR Convergence 2025
Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett¹, Marie-France Valois², Clifton Bingham³, Janet Pope⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Glen Hazlewood⁹, Bindee Kuriya¹⁰, Carter Thorne¹¹ and Vivian Bykerk¹², ¹McGill University, Beaconsfield, QC, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴University of Western Ontario, London, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷Retired, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Toronto - Toronto, Toronto, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: Pain, fatigue, and emotional distress are common in new RA patients. It is unclear whether co-occurring symptoms predict worse outcomes and progression to advanced therapies…
Abstract Number: 1326 • ACR Convergence 2025
Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², Yoshifumi Ohashi³, Shuji Asai² and Shiro Imagama², ¹Sobue Orthopedic Clinic Yatomi, Aichi, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Aichi Medical University, Graduate School of Medicine, Aichi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints but also has substantial implications for physical function. Persistent inflammation may…
Abstract Number: 0686 • ACR Convergence 2025
Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Ariane Herrick¹, Paul New², Graham Dinsdale³, Andy Vail², Joanne Manning³, Michael Hughes⁴, Will dixon⁵, Chris Taylor⁵, Mark Dickinson⁵ and Andrea Murray⁶, ¹The University of Manchester, UK, Aberdeen, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵The University of Manchester, Manchester, ⁶University of Manchester, Salford, United Kingdom
Background/Purpose: To facilitate clinical trials we previously developed a smartphone app to allow ‘tracking’ of systemic sclerosis (SSc)-related digital ulcers (DUs) and their associated pain…
Abstract Number: 0396 • ACR Convergence 2025
Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers
Catherine Lavallee¹, Samuel Garfinkle², Devlin Eckardt³, Stefanie Davidson⁴, Melissa Lerman⁵, Nicole Reitz⁶ and Kerry Hurlbut⁵, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania/CHOP, Philadelphia, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Mental Health, St. Louis, MO
Background/Purpose: Chronic noninfectious uveitis (CU) in pediatric patients is often asymptomatic and can cause vision loss, requiring frequent ophthalmologist visits and long-term treatment. This survey…
Abstract Number: 0308 • ACR Convergence 2025
Artificial Intelligence Assisted Extraction of Patient-Reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models
Jainesh Doshi¹, Stephen Batter¹, Yiyuan Wu², Alice Santilli¹, Sandhya Kannayiram³, Susan Goodman⁴ and Bella Mehta⁵, ¹Hospital for Special Surgery, New York, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Unstructured data in physician notes can be incredibly valuable, especially for understanding patient-reported outcomes (PROs), which are often mentioned in these notes.In this study,…
Abstract Number: 2677 • ACR Convergence 2025
Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease
Timothy Brandon¹, Rui Xiao², Daniel Lovell³, Edward Oberle⁴, Matthew Stoll⁵, Nancy A. Chauvin⁶, Michael Francavilla⁷, Walter P. Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶The Cleveland Clinic, Hummelstown, PA, ⁷Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, ⁸Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁹Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: This study assessed the timeline for the resolution of inflammation, changes in structural lesions at the sacroiliac joints (SIJ), and their correlation with patient-reported…
Abstract Number: 2341 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Ana-Maria Orbai¹, Dafna D. Gladman², Laura Coates³, Maarten de Wit⁴, Barbara Ink⁵, Rajan Bajracharya⁵, Patrick Healy⁶, Jérémy Lambert⁷ and Laure Gossec⁸, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁵UCB, Slough, England, United Kingdom, ⁶UCB, Morrisville, NC, ⁷UCB, Colombes, France, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The PsA Impact of Disease-12 (PsAID-12) questionnaire is…
Abstract Number: 1647 • ACR Convergence 2025
Clinical Phenotypes of Participants with Radiographic Osteoarthritis Attaining Patient Acceptable Symptom State in the Multicenter Osteoarthritis Study
Sarah Tilley¹, Michael LaValley², Brooke McGinley³, Cora Lewis⁴, James Torner⁵, David Felson³ and Tuhina Neogi⁶, ¹Boston University School of Medicine, Somerville, MA, ²Boston University School of Public Health, Arlington, MA, ³Boston University, Boston, MA, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵University of Iowa, Iowa City, IA, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: Osteoarthritis (OA) is a leading cause of pain and disability in older adults marked by progressive joint degeneration. Symptom trajectories vary: some experience persistent…
Abstract Number: 1290 • ACR Convergence 2025
Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Jin Xuan Zhou¹, Stephanie Fevrier², Paris Moaf², Lawrence Ng³, Asha Jeyanathan⁴, Louise Boulard², Deborah Levy¹, Linda Hiraki¹, Ashley Danguecan⁵ and Andrea Knight⁵, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease characterized by multi-organ inflammation, alongside high frequencies of mood disorders and cognitive impairment. Adverse Childhood…
Abstract Number: 0684 • ACR Convergence 2025
Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)
Antonia Valenzuela¹, Adriana Miguel Alvarez², Patricia E. Carreira³, Alejandra Babini⁴, Diana Rocío Gil Calderón⁵, John Pauling⁶ and Tatiana Rodriguez-Reyna², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁴Hospital Italiano, Córdoba, Argentina, ⁵Hospital Universitario Mayor MEDERI, Universidad del Rosario, Artmedica SAS, Bogotá, Colombia, ⁶North Bristol NHS Trust, Bristol, United Kingdom
Background/Purpose: Systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) significantly impacts patients’ quality of life, yet validated tools to assess this condition in Spanish-speaking populations are lacking. The…
Abstract Number: 0394 • ACR Convergence 2025
Predictors of quality of Life in a longitudinal cohort of patients with Uveitis, Juvenile Idiopathic Arthritis, and JIA-associated uveitis
andressa Guariento Ferreira Alves¹, Amy Cassedy², Virginia Miraldi Utz³, Alexandra Duell³, Megan Quinlan-Waters⁴, Nicole Reitz⁵, Sheila Angeles-Han⁶ and Melissa Lerman⁷, ¹The Children's Hospital of Philadelphia, Philadelphia, PA, ²Cincinnati Children's hospital medical center, cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, CCHMC, ⁵Department of Mental Health, St. Louis, MO, ⁶Cincinnati Children's Hospital, Cincinnati, OH, ⁷Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Uveitis, juvenile idiopathic arthritis (JIA), and JIA-associated uveitis (JIA-U) greatly influence children's quality of life (QOL). Our aim is to identify demographic, disease, and…
Abstract Number: 0282 • ACR Convergence 2025
Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
Shiri Keret¹, Raisa Lomanto Silva², Irada Choudhuri³, Eugenia Gkiaouraki³, Tanya Chandra³, Nantakarn Pongtarakulpanit³, Shreya Sriram³, Niladri Bhowmick³, Vaidehi Kothari³, Kaushik Sreerama Reddy³, Eaman Alhassan⁴, Anushka Aggarwal⁵, Maha Almackenzie⁶, Siamak Moghadam-Kia⁴, Dana Ascherman⁷, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Bnai Zion Medical Center, Atlit, Israel, ²Massachusetts General Hospital, Boston, MA, ³University of Pittsburgh Medical Center, Pittsburgh, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Indraprastha Apollo Hospital, New Delhi, India, ⁶Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: The six myositis core set measures (CSMs) are widely utilized to assess disease activity in idiopathic inflammatory myopathies (IIM). However, their association with how…
Abstract Number: 2654 • ACR Convergence 2025
Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Alisa Stephens Shields², Peter Merkel², Jessica Alvey³, Shervin Assassi⁴, Elana Bernstein⁵, Sonali Bracken⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Jessica Gordon¹¹, Faye Hant¹², Monica Harding¹³, Laura Hummers¹⁴, Dinesh Khanna¹⁵, Kimberly Lakin¹¹, Dorota Lebiedz-Odrobina¹³, Yiming Luo⁵, Ashima Makol¹⁶, Maureen Mayes¹⁷, Zsuzsanna McMahan¹⁸, Jerry Molitor¹⁹, Duncan Moore²⁰, Carrie Richardson²¹, Ami Shah¹⁴, Ankoor Shah²², Brian Skaug²³, Virginia Steen²⁴, John VanBuren¹³, Elizabeth Volkmann²⁵, Carleigh Zahn¹⁵ and Nora Sandorfi², ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁵Columbia University, New York, NY, ⁶Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁷Massachusetts General Hospital, Boston, MA, ⁸Stanford University, Stanford, CA, ⁹Scleroderma Research Foundation, San Francisco, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Hospital for Special Surgery, New York, NY, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of Utah, Salt Lake City, UT, ¹⁴Johns Hopkins Rheumatology, Baltimore, MD, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷UT Health Houston Division of Rheumatology, Houston, TX, ¹⁸UT Health Houston, Houston, TX, ¹⁹University of Minnesota, Minneapolis, MN, ²⁰Northwestern Memorial Hospital, Chicago, IL, ²¹Northwestern University, Chicago, IL, ²²Duke University, Durham, NC, ²³UTHealth Houston Division of Rheumatology, Houston, TX, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: To determine the frequency and extent of discordance between patient and physician global assessments of disease in early systemic sclerosis and identify factors associated…
Abstract Number: 2301 • ACR Convergence 2025
Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Sara M. Stern¹, Angela Merritt², Ludovic Trinquart³, Emma Barnboym⁴, Michelle LeeBravatti³, Suzy Richins⁵, Tressie L. Rollins⁵, Hanna M. Salzman⁵, Marisha Palm³, Cortney M. Wieber⁶, Hermine Brunner⁷ and Nora G. Singer⁸, ¹University of Utah, Salt Lake City, UT, ²Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ³Tufts University School of Medicine, Boston, MA, ⁴The MetroHealth System at Case Western Reserve University School of Medcine, Cleveland, OH, ⁵Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁶Institute for Clinical Research and Health Policy Studies (ICRHPS) and CTSI, Tufts School of Medicine, Boston, MA, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Childhood Sjogren Disease (cSjD) is a rare disease that presents with a wide variety of symptoms. Compared to adult SjD, cSjD more frequently manifests…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].